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Abstract
Objects: The diffusion-based spherical mean technique (SMT) provides a novel
model to relate multi-b-value diffusion magnetic resonance imaging (MRI) data
to features of tissue microstructure. We propose the first clinical application of
SMT to image the brain of patients with multiple sclerosis (MS) and investigate
clinical feasibility and translation. Methods: Eighteen MS patients and nine age-
and sex-matched healthy controls (HCs) underwent a 3.0 Tesla scan inclusive
of clinical sequences and SMT images (isotropic resolution of 2 mm). Axial dif-
fusivity (AD), apparent axonal volume fraction (Vax), and effective neural diffu-
sivity (Dax) parametric maps were fitted. Differences in AD, Vax, and Dax
between anatomically matched regions reflecting different tissues types were
estimated using generalized linear mixed models for binary outcomes. Results:
Differences were seen in all SMT-derived parameters between chronic black
holes (cBHs) and T2-lesions (P ≤ 0.0016), in Vax and AD between T2-lesions
and normal appearing white matter (NAWM) (P < 0.0001), but not between
the NAWM and normal WM in HCs. Inverse correlations were seen between
Vax and AD in cBHs (r = 0.750, P = 0.02); in T2-lesions Dax values were
associated with Vax (r = 0.824, P < 0.0001) and AD (r = 0.570, P = 0.014).
Interpretations: SMT-derived metrics are sensitive to pathological changes and
hold potential for clinical application in MS patients.
Introduction
Axonal injury is a key element in the pathology of multi-
ple sclerosis (MS) and a major determinant of patients’
disability.1 Because capturing and characterizing axonal
damage in MS patients in vivo is challenging,2 there
remains a pressing need to identify a magnetic resonance
imaging (MRI) biometric indicative of axonal quantity.
This biomarker would allow for the detection of micro-
scopic damage before symptoms and irreversible tissue
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damage appear, potentially optimizing treatment person-
alization based on an accurate characterization of tissue
injury. Lack of this biomarker is an impediment to a
responsible design and conduct of phase II and phase III
clinical trials on neuroprotection,3 ultimately making MS
an incurable disease.
Combined MRI-histopathologic studies provided the
demonstration that lesions appearing as hypo-intense on
T1-weighted spin echo (T1-w SE) MRI in the absence of
corresponding enhancement on postcontrast sequences,
namely, chronic black holes (cBHs), represent areas of
more advanced disease pathology and axonal loss com-
pared with lesions that show only hyper-intense signal on
T2-w MRIs.4 Although cBHs’ count is used as semiquan-
titative tool to measure axonal integrity, this count
remains poorly specific to the degree of axonal pathology.
cBHs’ visibility is also affected by the MR field strength
and acquisition parameters. MR spectroscopy (MRS) and
the quantification of the neuronal metabolite N-acetyl
aspartate (NAA) has made it possible to infer on axonal
damage and secondary loss in MS.5 Technical disadvan-
tages such as the long acquisition time and poor image
resolution challenge the advancement of MRS to clinical
and research utilization.2
Diffusion-based imaging offers an opportunity to over-
come the limitations of these two techniques.6 In diffu-
sion-based MRI the signal is sensitive to the random
motion of water molecules, which is hindered by barriers
like myelin and axons in human brains. Diffusion tensor
imaging (DTI) models and measures anisotropic diffusion
along multiple directions, yielding measures of axial diffu-
sivity (AD = diffusion parallel to fiber bundles), radial
diffusivity (RD = diffusion perpendicular to fiber bun-
dles), mean diffusivity (MD = diffusion across all direc-
tions) across all directions, and the derived fractional
anisotropy (FA). Although it is recognized that a complex
relationship links these metrics with tissue biological
changes, RD and AD values are referred as proxy of mye-
lin and axonal quantity, respectively.7
A major limitation of DTI is that its associated signals
arise from all water compartments within a voxel.7 Hence,
fluid accumulation typically seen during inflammation or
end stage cavitation8,9 can significantly contaminate the
derived metrics. Several advanced multi-compartment dif-
fusion models have been developed to isolate and separate
the signal contribution deriving from different compart-
ments, thus increasing the ability to detect specific tissue
structures. For example, diffusion basis spectrum imaging
(DBSI) developed by Wang and collaborators10–12 detects
increased cellularity and water content in MS. The neurite
orientation dispersion and density imaging (NODDI) is a
simple and practical model-based diffusion MRI tech-
nique for estimating microstructural complexity such as
volume fraction and dispersion of dendrites and axons
in vivo.13–15
The Spherical Mean Technique (SMT) provides an
alternative model to relate multi-b-value diffusion MRI
data to features of tissue microstructure, recently devel-
oped by Kaden and collaborators.16,17 SMT removes the
orientation dependence of diffusion MRI signals by taking
the averages of diffusion signals over all gradient direc-
tions for each b shell.16–18 This not only simplifies data
analysis but also significantly improves the signal-to-noise
ratio (SNR), helping to reduce interscan variations. In
contrast to DTI derived metrics, which are sensitive to
both fiber orientation distribution and fiber microstruc-
ture, SMT derived measures are sensitive to fiber compo-
sition only, thus more specific to tissue biology. On the
other hand, SMT avoids some of the strong modeling
assumptions in NODDI and has less computational
demands, while having similar modest acquisition
requirements to NODDI (two non-zero b-values) and
much simpler acquisition requirements compared with
DBSI.
The SMT model has two compartments, that is, the
intra-axonal and extra-axonal space. In the intra-axonal
compartment, SMT models (1) the parallel diffusivity and
(2) perpendicular diffusivity, which is set to zero because
of the very small diameter of the axons; and the (3)
apparent volume fraction (Vax). In the extra-axonal com-
partment, SMT models (1) the parallel diffusivity and (2)
perpendicular diffusivity, which depends on the packing
density of the (myelinated) axons; and the (3) volume
fraction 1  Vax. Relevant to the studies we propose,
SMT estimates, the apparent axonal volume fraction (Vax)
and the effective neural diffusivity (Dax). Vax is a proxy of
the (%) signal fraction arising from axons inside a given
voxel, hence relating to the apparent volume fraction of
occupied by axons within a given voxel. Dax averages the
parallel diffusivity over the intra- and extra-axonal water
pools and provides indirect estimates of microenviron-
ments inside the axons and their surroundings.
Work in our group has validated SMT technique
against histology using mice with tuberous sclerosis com-
plex and age-matched controls.16 This animal model is
more suitable to detect axonal injury in brain than that
of experimental autoimmune encephalomyelitis typically
used to study MS, as free from the inflammatory compo-
nent which can function as confounding factor in a vali-
dation process. Animals with tuberous sclerosis complex
showed significantly decreased values of Vax across several
affected brain regions compared with controls. A decrease
in the myelinated axon fraction (with the myelin fraction
excluded) was mirrored by a reduction of the MRI-based
Vax.
16 Although obtained with a different disease model,
the provided validation against axonal histology is
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fundamental and applicable to any condition affecting
myelin and axonal integrity.
Given that axonal injury and loss are markers of MS
pathology and SMT-derived indices report on the fraction
of viable axons, we hypothesize that indices derived from
SMT are sensitive to different degrees of pathological
changes and, thus hallmarks of neurodegenerative tissue
injury in patients. To test this hypothesis, we acquired
SMT in a cohort of MS patients and of age- and sex-
matched healthy controls (HCs). We derived Vax and Dax,
measurements in tissue with different degree of injury
based on gold-standard conventional clinical MRI with
the goal of assessing clinical feasibility and translation for
MS patients imaged at a 3.0 Tesla (3T) scanner.
Methods
Study design and cohort
This cross-sectional study was performed as collaborative
project between the Neurology and the Radiology Depart-
ments at the Vanderbilt University Medical Center
(VUMC) and the University College London. The study
was approved by the VUMC Institutional Review Board
and each subject signed an informed written consent
prior to be enrolled. All methods were performed in
accordance with the relevant guidelines and regulations.
Eighteen MS patients and nine age and sex-matched
HCs were consecutively included. Patients were required
to be ≥6 months free from clinical relapses/steroids
administration and to have no disease activity docu-
mented by a postcontrast clinical scan within the previous
month (Table 1). Exclusion criteria for both patients and
HCs were: (1) contraindication for a brain MRI; (2) preg-
nancy and/or breastfeeding; (3) other brain autoimmune,
neoplastic or infectious diseases, current or past
≥6 months longer history of uncontrolled hypertension,
diabetes, hyperlipidemia, and migraine; (4) inability to
provide a written consent. Each subject underwent a clini-
cal evaluation and a brain MRI scan within 2  2 weeks.
In patients, the clinical exam consisted of obtaining an
accurate history and rating the disability using the
Expanded Disability Status Scale (EDSS)19 score and the
average of two trials for the Timed 25-Foot Walk Test
(T25-WT).20 For HCs, morbidities were ruled out via a
questionnaire. Four subjects were imaged twice within
2  2 weeks to compute interscan variability measures.
MRI protocol and image postprocessing
(Fig. 1)
Brain MRIs were performed using a Philips Achieva 3T
whole-body scanner equipped with a 32-channel receiver
head coil. All sequences were acquired without gap. Whole-
brain T1-w and T2-w turbo SE (TSE), T2-w fluid attenu-
ated inversion recovery (FLAIR) images were obtained at a
resolution of 0.4 9 0.4 9 2 mm3. SMT images were
acquired with isotropic resolution of 2 mm. Diffusion MRI
was acquired using single-shot, SE echo planar imaging
(EPI) readout, echo time (TE) = 74 msec, repetition time
(TR) = 13.5 sec, 2 b shells (1000 and 2500 sec/mm2), 90
diffusion directions (45 directions on each b shell) accord-
ing to a previously reported approach.21 An additional
b = 0 image volume was acquired with reversed phase-en-
code EPI blips to correct for image distortion.
For each subject, all diffusion MRI data were corrected
to remove susceptibility and eddy-current induced distor-
tion using topup and eddy toolbox in FSL (https://fsl.fm
rib.ox.ac.uk/fsl/). Two parametric maps, Vax and Dax were
fitted according to the method reported previously.17 In
addition, 3D DTI-based parametric maps AD were gener-
ated. Thereafter, T1-w TSE, T2-w FLAIR MRIs, and each
of the SMT derived parametric maps were coregistered to
the T2-w TSE image using an affine coregistration (flirt
toolbox22 in FSL, https://fsl.fmrib.ox.ac.uk/fsl/). Figure 1
displays the array of reconstructed maps and registered
clinical scans of an MS patient chosen as example.
Analysis of SMT-derived metrics across
tissue types (Fig. 2)
To quantify differences between various tissues types,
given the well-known variability in axonal number and
Table 1. Demographic, clinical, and MRI characteristics of patients
Patients (n = 18) HCs (n = 9) P-value
Age 45.5  14.6 41.7  10 0.486*
Sex (females/males) 13/6 5/4 0.507**
Ethnicity 2 African
American 16
Caucasians
8 Caucasians
1 Asian
–
MS type (CIS/RRMS/
SPMS)
4/11/3 – –
Disease duration
(years)
12.1  10.6 – –
EDSS score 1 (0–6.5) – –
T25-FW (seconds) 10:37  18:12 – –
T2-lesions volume
(cm3)
14.9  21.3 – –
cBHs volume (cm3) 7.3  7.5 – –
Quantitative data are expressed in mean  SD (minimum-maximum
value) except for the EDSS score for which median (minimum-maxi-
mum values) are reported; cBHs, chronic black holes; CIS, clinically
isolated syndrome; EDSS, expanded disability status scale; RRMS,
relapsing remitting multiple sclerosis; SPMS, secondary progressive
multiple sclerosis. P values generated by *unpaired Student’s t-test
and a **v2 test.
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Figure 1. Coregistered anatomical MRI and parametric maps. Top row shows T1-w TSE (A), T2-w TSE (B), and T2-w FLAIR (C); bottom row
shows AD (D), Vax (E), and Dax (F) maps. Note the cBH visibility on T1-w SE image and Vax map (white arrow).
Figure 2. Schematic representation of lesions delineation. Lesion delineation is illustrated. Each cBH (yellow region-of-interest (ROI) in A and B)
was anatomically matched with a correspondent T2-lesion (green ROI in A and B); each T2-lesion (green ROIs in C) was anatomically matched
with contralateral areas of normal appearing white matter (NAWM, blue ROIs in C).
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diameter in different areas of the brain, anatomically
matched regions of interest (ROIs) were generated
(Fig. 2). This evaluation was achieved by inspecting T1-w
and T2-w coregistered images at the same time and
ensuring presence/absence of a specific tissue type in the
area of interest and in the contralateral one. ROIs (≥10
voxels)8 were delineated using graphic tools available in
MIPAV (https://mipav.cit.nih.gov). All generated masks
were then overlaid on Vax, Dax, and AD parametric maps
and correspondent quantities derived using mathematical
tools in MIPAV.
ROIs were placed on areas of normal appearing white
matter (NAWM), T2-lesions and cBHs in patients, and in
normal WM (NWM) in HCs. Tissue type classification
was based on visual inspection performed by a junior
investigator (GF) and confirmed by a senior investigator
(FB).
NAWM was defined as any area displaying normal sig-
nal on T2-w TSE and FLAIR images. Care was taken to
avoid areas of dirty WM23 and those in the vicinity of a
lesion. T2-lesions were defined as any area of hyperin-
tense signal on T2-w TSE and FLAIR images24 that did
not have a corresponding hypo-intense signal on T1-w
TSE MRI. cBHs were defined as areas of hypo-intense sig-
nal on T1-w TSE corresponding to a region of hyperin-
tense signal on T2-w TSE and FLAIR images.25 None of
the lesions was known to be in active stage given our
inclusion criteria.
This tissue type classification was based on the known
concepts that: (1) a considerable amount of pathology
may be found in areas of MS brains appearing as “nor-
mal” on conventional MRI scans1; (2) T2-lesions without
a corresponding cBH carry pathological traits that are less
severe than cBHs8; and (3) cBHs are expected to harbor
variable degrees of axonal injury.4
To quantify differences between NAWM (patients) and
NWM (HCs), ROIs were delineated in the internal cap-
sula only (chosen as representative tract). The internal
capsula was localized by two investigators (GF and FB)
looking at the T2-w images against anatomical atlases.
For this last set of comparisons, care was taken that all
areas had the same size which was 80 voxels.
Analysis of SMT-derived metrics and lesion
burden
To assess the associations between overall lesion burden
and SMT-derived metrics, whole-lesion load on T2-w and
T1-w images was computed. To obtain lesion volume, we
used the procedures previously described.26 In brief: we
first identified and delineated all cBHs on T1-w TSE
MRIs and all hyperintese WM lesions on T2-w FLAIR.
Thereafter we created a subtraction mask in MATLAB
(Mathworks, Natick, MA) by removing all the cBHs from
the hyperintense lesions. The cBHs masks were used to
compute the cBHs volume and the subtraction mask was
used to compute the overall T2-lesion burden, using
mathematical tools available in MIPAV.
Interscan variability measurements
For interscan variability measurements, ROIs were
traced on T2-w SE MRI randomly obtained with the
first or the second scan. SMT imaging derived maps at
each time point were then registered into the T2-w SE
space selected for ROI labeling using the FSL software
package as described above. For each pair of scans,
ROIs were selected in NAWM/NWM and in WM
lesions. Care was taken that all areas had the same size
which was 80 voxels. The average SMT- and DTI-mea-
sures for these ROIs were then calculated. Quantities
on 96 ROIS were collected in NWM, MAWM and
WM lesions.
Statistical analyses
Differences in age and sex between patients and HCs
were assessed using t-test and Chi-square test, respec-
tively. Generalized linear mixed models for binary out-
comes were used to assess differences in each of the MRI
metrics between different tissues types. In these models,
the type of MR measurement (Vax, Dax, and AD) was
treated as a fixed-effect factor, and a nested random
effect factor for ROI and patient ID was included to take
into consideration the data correlation structure.
Adjusted odds ratios (OR) with corresponding 95% con-
fidence interval (CI) and the Akaike information crite-
rion (AIC) values were reported. Some of the original
values were very small, which resulted in extreme OR
values. Therefore, each variable was scaled to the degree
needed to have easy-to-interpret OR ranges. Specifically,
Vax, Dax, and AD were scaled 10 (Vax) and 10,000 (Dax
and AD) times in all generalized linear mixed models.
Associations among different MRI measures and between
MRI and clinical variables were assessed using a Spear-
man’s correlation.
Interscan variability in Vax, Dax and AD was assessed
using Spearman’s correlation analyses, intra-class correla-
tion analysis and linear mixed-effect models. These mod-
els estimated differences between the two measurements
taken 2 weeks apart while adjusting for the fixed-effect
factors, for example, scan (first/second) and ROI (type).
The nested random effect factors were subjects and scan.
MRI measurements from the two scans were visualized
with smoothed scatter plots. Spearman’s correlation coef-
ficients were calculated between the two scans.
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Results
All recruited participants tolerated the entire brain MRI
scan and there were no missing data.
Interscan variability (Fig. 3)
As represented in Figure 3, Spearman’s correlation analy-
ses showed that scan-1 and scan-2 measurements were
highly correlated (r = 0.654, P < 0.0001 for Vax,
r = 0.367, P = 0.010 for Dax, and r = 0.809, P < 0.0001
for AD). Linear mixed-effect models showed that Vax
(P = 0.337), Dax (P = 0.326) and AD (P = 0.966) values
were consistently similar between the two scans. Table 2
reports intraclass correlation coefficients and 95% CI of
each pair of measurements.
Analysis of cBHs vs T2-lesions (Fig. 4)
This analysis was obtained in 209 cBHs which were com-
pared with 209 contralateral T2-lesions identified from
nine patients. Vax [P < 0.0001, AIC = 446.5, OR = 6.25,
95% CI = (4.28, 9.52)] values were consistently lower in
cBHs compared with T2-lesions. Dax [P = 0.0016,
AIC = 571.2, OR = 0.85, 95% CI = (0.77, 0.94)] and AD
[P < 0.0001, AIC = 482.4, OR = 0.68, 95% CI = (0.61,
0.74)] values were higher in cBHs compared with T2-le-
sions. Vax values decreased by 63.4  45.5% in cBHs vs
T2-lesions, whereas Dax and AD values increased by
3.6  7.9% and 14.1  9.1%, respectively.
In cBHs, only Vax and AD measures were significantly
associated (r = 0.750, P = 0.02).
Analysis of T2-lesions vs NAWM (Fig. 5)
This analysis was obtained in 606 T2-lesions which were
compared with 606 contralateral ROIs identified from 18
patients. Vax [P < 0.0001, AIC = 1566.9, OR = 0.54, 95%
CI = (0.47, 0.61)] values were lower and AD [P < 0.0001,
AIC = 1614.5, OR = 1.31, 95% CI = (1.23, 1.41)] values
higher in T2-lesions compared with NAWM ROIs. Vax
values decreased by 36.5  9.7%, whereas AD values
increased by 8.8  0.5% in T2-lesions compared with
NAWM. Dax was 3.0  9.4% higher in T2-lesions com-
pared with NAWM ROIs. This increment, though, did
not correspond with significantly different values between
the two tissues types.
In this subset of lesions, Dax values were significantly
associated with Vax (r = 0.824, P < 0.0001) and AD val-
ues (r = 0.570, P = 0.014).
Analysis of NAWM vs NWM (Fig. 6)
This analysis was obtained in 136 NAWM ROIs which
were compared with 72 NWM ROIs identified from 18
patients and all nine HCs.
To ensure proper anatomical correspondence, compar-
isons between NAWM and NWM regions was limited to
areas of the internal capsula. No group-differences were
seen in Vax [P = 0.961, AIC = 35.5, OR = 0.95, 95%
CI = (0.054, 47.25)], Dax [P = 0.915, AIC = 35.5,
OR = 0.96, 95% CI = (0.30, 4.00)] and AD [P = 0.801,
AIC = 35.4, OR = 0.68, 95% CI = (0.0056, 10.50)]. These
nonsignificant differences corresponded to percent drops
of 2.9% in Vax, and 5.4% and 5.8% increases in Dax and
AD between NAWM and NWM. NAWM Vax was signifi-
cantly correlated with NAWM Dax (r = 0.914,
P < 0.0001).
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Figure 3. Correlation plots of scan-1 and scan-2 values. Correlation plots showing the associations between scan-1 and scan-2 measurements of
Vax (A), Dax (B), and AD (C).
Table 2. Measures of interscan variability
Variable
Intraclass correlation
coefficient (ICC)
95% Confidence interval
of ICC
Vax 0.424 0.004/0.483
Dax 0.300 0.074/0.675
AD 0.275 0.085/0.637
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Associations between conventional
radiological measures and Vax/Dax
measurements
This explorative analysis was limited to only the patients
who contributed to the measurements, that is, nine
patients for cBHs Dax and Vax and 18 patients for T2-le-
sions and NAWM ROIs. Significant correlations emerged
between cBHs Dax and cBHs volume (r = 0.826,
P = 0.006). None of the diffusion-based metrics measured
in T2-lesions and NAWM correlated significantly with
cBHs and T2-lesion volume. Statistical trends were seen in
the associations between T2-lesion volume and Dax mea-
sured in T2-lesions (r = 0.428, P = 0.076) and between
NAWM AD and cBHs volume (r = 0.426, P = 0.088).
Associations between clinical measures and
Vax/Dax measurements
As seen for the associations with radiological metrics, this
explorative analysis was limited to only the patients who
contributed to the measurements. Nine patients for cBHs
Dax and Vax and 18 patients for T2-lesions and NAWM
ROIs. We did not find any significant association between
MRI and clinical metrics. A trend was seen only between
T2-lesion Vax (r = 0.424, P = 0.079) and T25-WT scores.
Discussion
We deliver the first clinical application of SMT as an
imaging tool to probe axonal integrity in brains of
patients with MS and show the feasibility of our tech-
nique for an in vivo marker of axonal damage. SMT pro-
duces two novel metrics namely Vax and Dax. Although
changes in Vax and Dax follow the same directions of
those seen with AD, SMT offers a novel framework in
that while AD depends on the diffusivity parallel to the
axons and their orientation distribution, SMT fully factors
out the unwanted effect of the axon orientation distribu-
tion (e.g., fiber crossings and intrabundle orientation dis-
persion) and provides estimates of axonal configuration,
only. The removal of orientation dependency increases
the specificity of the measurement to axonal integrity,
which is fundamental to properly assess disease in human
brains.
This translates into the delivery of a more accurate
information regarding the degree of injury of myelinated
axons. The latter is important information for patients
with MS since axonal injury is a key element of their
physical and cognitive disability and represents an end-
stage, irreversible disease trait. Treatment strategies target-
ing axonal counts are much needed to arrest MS progres-
sion and an imaging biomarker accurate proxy of this
count is fundamental to assess drugs effect.
Vax, Dax, and AD values were found to be consistently
different between cBHs and T2-lesions; statistical analyses
yielded comparable AIC, hence proving that from a statis-
tical standpoint, the degrees of significance were compa-
rable. However, in cBHs Vax values decreased by about
63%, whereas Dax and AD values increased only by about
4% and 14%, respectively. The magnitude of these differ-
ences points toward a different level of sensitivity to
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pathology. While Vax provides indirect estimates of the
apparent axonal volume fraction, Dax and AD are also
more sensitive to the overall lesion, intra- and extra-ax-
onal, microenvironment where several factors may modu-
late measurements.
cBHs are known to harbor a diminished number of
axons,4 whereby the empty space left by axonal loss is
filled with cerebrospinal fluid (CSF).8 In cBHs axonal
death is for the most part secondary to myelin injury,
thus axonal loss is nearly always accompanied by myelin
death. In this pathological scenario, we argue that
increases in AD capture the degree of CSF quantity out-
side residual axons but also water which accumulates
inside axons when swelling proceeds death; decreases in
Vax, instead, are more reflective of viable remaining intact
(myelinated) axons, irrespective of their sizes or the sur-
rounding CSF. Differences in the degree of associations
between Vax and AD or Dax values may also be intrinsic
to the biophysics of these parameters. AD is sensitive to
both orientation and microstructural effects, whereas Dax
is only sensitive to microstructural features as the orienta-
tion distribution effect is factored out by the model. It is
likely that in cBHs modifications of the orientation distri-
bution play a larger role compared with that of
microstructural changes due to the actual tissue loss and
water accumulation, thus rendering AD (more than Dax)
reflective of Vax values.
Analyses related to T2-lesions in comparisons to
NAWM were obtained in a larger number of ROIs and
patients since virtually every patient presented with
lesions on T2-w MRIs. As seen for cBHs, Vax values were
lower and AD values higher in T2-lesions compared with
NAWM ROIs, and AICs were comparable. Vax values
decreased by 36%, whereas AD values increased by 9% in
T2-lesions compared with NAWM. Dax measures were
minimally higher in lesions compared with NAWM but
this difference did not reach statistical significance. Dax
was significantly associated with T2-lesions Vax and AD.
Such associations differ from that seen in cBHs in that
Vax and Dax were positively correlated.
Three possible interpretations, not mutually exclusive,
can explain the findings of Vax reduction in T2-lesions.
First, our data suggest that axonal injury is not a feature
of cBHs only and that, although to a less extent, chronic
T2-lesions may harbor some degree of axonal death. Sec-
ond, one shall keep in mind that Vax may also be affected
by myelin loss not necessarily mirrored by axonal death.
Myelin degradation makes the tissue substrate less densely
packed and may lead to an increase of exchange between
intra- and extra-axonal water, which the SMT model
assumes as negligible. Untangling the effect of axonal and
myelin pathology is difficult in T2-lesions where: (1) the
pathological features are more heterogeneous than in
cBHs; (2) most of the axons are expected to be viable; (3)
remyelination and demyelination may be tightly spatially
connected. This may explain also the complex and
intriguing results derived from correlation analysis. Last,
in the presence of chronic inflammation and associated
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free water content changes in the extracellular space, the
T2 relaxation time and diffusion signal coming from the
extracellular compartment increase. In SMT, the higher
intensity of the signal from the extracellular space will
translate into a higher signal fraction (1  Vax) or lower
Vax. In the absence of compartmental T2 relaxation time
data, the determination of this effect remains elusive.
We argue that the pathological heterogeneity of T2-le-
sions explains the similarity in Dax values between these
lesions and NAWM as well as the positive associations
between Vax and Dax values.
Different histopathological stages, macroscopically char-
acterized by changes in axonal size, feature the pathway
toward atrophy and consequential death.27 Chronic axo-
nal injury is characterized by the accumulation of axonal
proteins in the proximal stump and end bulbs of spher-
oids containing cytoskeletal phosphorylated proteins, such
as phosphorylated neurofilament. Axons at this stage are
unusually thick due to chronic axonal reaction to
demyelination. When the damage is secondary to chronic
demyelination, axons tend to swell, accumulate nonphos-
phorylated neurofilaments and lose phosphorylated neu-
rofilaments. These changes in phosphorylation are
consequences of chronic demyelination. Atrophy is a fur-
ther-late common-end stage phenomenon, characterized
by decreased axonal volume and thickness and distur-
bance of neuronal protein synthesis.27
It is well-known that all these processes, along with
demyelination alone, re-myelination, and gliosis, may co-
exist in T2-lesions. Imaging cannot distinguish any of
these pathologies but can indirectly proxy all of them by
depicting changes in microstructural integrity (changes in
protein content), water content (swelling), and overall
axonal quantity (axonal death). All these changes alter
water diffusion microenvironment and eventually alter
the diffusion MRI signals in potentially opposite direc-
tions. Thus, lack of end changes in Dax and the positive,
in a way “paradoxical” associations seen between Vax and
Dax may be the result of these heterogeneous pathological
processes along with sensitivity of Vax to both axonal and
myelin density when axonal loss has not occurred.
Differences between NAWM and NWM Vax, Dax, and
AD led to negative results though a strong trend was seen
for Vax. Several factors, not necessarily mutually exclusive
may explain our data. First NAWM axonal pathology
may not necessarily be present in all MS patients,28 espe-
cially if one considers that (1) about 50% of patients
included in our study had minimal disability EDSS ≤1.0
and (2) that our study targeted only a selected group of
WM fibers. Second, it is expected that the magnitude of
the differences between NAWM/NWM is smaller than the
ones measurable between different lesion types or between
lesions and NAWM, thus it is possible that our sample
size was not powered to detect them. Third, opposite to
as seen in lesions, axonal injury in NAWM is not sec-
ondary to demyelination rather to Wallerian (primary)
axonal degeneration which eventually leads to secondary
demyelination. Thus, several injured axons may still be
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myelinated, a factor that may prevent significant changes
in diffusion-based parameters to be measured.
Notwithstanding the above considerations, it is interest-
ing to note that Vax measurements were nearly signifi-
cantly different between the two groups of ROIs, whereas
AD and Dax were not. The data indicate once again the
ability of Vax to depict pathologies that are different and
are likely measurable earlier in the disease course than
those captured from Dax and AD.
Of all explored associations, the only one that showed
a statistically relevant (inverse) significance was that
between cBHs Dax values and cBHs volume. In lack of
other data corroborating the biological meaning of these
findings, any interpretation remains limited and vulnera-
ble. It is important to underscore that SMT metrics were
derived only from a limited number of patients and
lesions. On the contrary, volume measures reflect the
overall lesion burden each individual patient had. This
factor, in addition to clinical heterogeneity of the study
cohort and its relatively small size make it not suitable to
answer specific biological-clinical questions.
Study limitations and conclusions
As stated, our work lacks data regarding clinical impact
of SMT-derived metrics. While we acknowledge that this
is an important limitation, we also point out that this line
of research was outside the scope of our work. Assessing
the ability of SMT to quantify tissue changes was our
study goal and it is the first important pre-requisite for a
given sequence to be further applied on larger clinical
scale. Our study is part of a larger project the goal of
which is assessing the role of SMT-derived metrics as
hallmarks of neurodegenerative tissue injury and severity
of neurological dysfunction.
We also lack analysis of active lesions, featured by con-
trast enhancement and overt blood–brain barrier break-
down. This topic was also outside our initial scope of
proving feasibility of SMT in patients with MS. It is the
focus of future work as very important from both a bio-
logical and a technical stand point.
Another important limitation is that, except for myelin
water that is invisible at the echo times used in clinical dif-
fusion MRI scans, the SMT model assumes uniform T2 val-
ues (i.e., the same value for intra- and extra-axonal spaces).
Although this assumption has been used extensively thus
far, a recent study29 reported that the intra-axonal T2 is
longer than the extra-axonal T2, which may result into a
biased estimation of the apparent Vax obtained using SMT.
The same study also found that the intra-axonal T2 could
be dependent on the angle of the tract relative to the main
magnetic field, which suggests that subject’s head orienta-
tion itself could influence the results. A possible solution is
to perform combined diffusion-relaxometry measurements.
In terms of clinical translation, though, one needs to be
cautious as acquiring T2-maps adds another dimension of
acquisition and significantly increases the total scan time.
By contrast, SMT provides a simplified and efficient means
to evaluate the apparent axonal volume fraction with clini-
cally feasible scan time, if one is mindful of the caveat that
absolute values may be confounded by the multi-compart-
ment T2 relaxation.
In conclusion, we propose the first clinical application
of SMT in brain of patients with MS. Our results yield
intriguing observations which overall testify for the appli-
cability of this technique in patients with brain and spinal
cord16 conditions featured by neurodegeneration. Our
group is committed to future work to resolve some of the
issues related to the complexity of the technique and its
findings. Notwithstanding the discussed limitations of our
study, we offer a solid demonstration that SMT provides
a conceptually novel framework to look at axonal pathol-
ogy in MS patients and represent a step forward in the
in vivo characterization of MS pathology.
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